Gallaudet University Responds to Gene Editing Therapies, Affirms Deaf Identity
Gallaudet University, a leading institution for deaf and hard-of-hearing students in Washington, DC, has officially responded to advancements in gene editing therapies for deafness, stating that deaf lives are not deficits to be corrected.
Washington, DC, November 11, 2026 — Gallaudet University, an institution recognized globally for its commitment to deaf and hard-of-hearing students, has issued a formal statement addressing the ongoing advancements in gene editing therapies that aim to treat or prevent deafness. Located in Washington, DC, the university has articulated its position that deafness should not be viewed as a condition requiring correction.
The university’s response comes at a time when scientific research into gene editing technologies, such as CRISPR, is making significant strides. These therapies hold the potential to alter genetic mutations that cause hearing loss, raising profound ethical and societal questions about the future of deafness and the deaf community.
In its statement, Gallaudet University emphasizes that the deaf community is a rich and vibrant culture, and that deaf individuals lead full and meaningful lives. The institution asserts that classifying deaf lives as deficits that need to be corrected through medical intervention overlooks the identity, experiences, and contributions of deaf people. This perspective highlights a long-standing debate within the deaf community regarding the medicalization of deafness versus its recognition as a cultural identity.
Gallaudet University’s stance reinforces its core mission to empower deaf and hard-of-hearing individuals through education and advocacy. The university’s position underscores the importance of respecting deaf identity and culture, and ensuring that technological advancements are considered within a broader context of human diversity and individual rights. The institution did not provide specific details on how it plans to engage with ongoing research or policy discussions related to gene editing therapies, focusing instead on the principle that deaf lives are inherently valuable and should not be framed as problems to be solved.
Story summarized from the original created by Sophia Solano on www.washingtonpost.com, see more information here.
